SCHEMBL8427583

SCHEMBL8427583

NCCCC[C@H](NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC15A2 Q16348 1/20 0.46
ERAP2 Q6P179 4/20 0.40
LNPEP Q9UIQ6 4/20 0.40
TERT O14746 1/20 0.40
SLC6A5 Q9Y345 1/20 0.38
ERAP1 Q9NZ08 2/20 0.37
FOLH1 Q04609 1/20 0.37
MMP2 P08253 1/20 0.36
ECE1 P42892 1/20 0.35
OPRD1 P41143 1/20 0.35
CD40 P25942 1/20 0.34
NOD1 Q9Y239 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9747810 1.00 SLC15A2 (0.46) SLC15A2ERAP2LNPEPTERTSLC6A5
SCHEMBL9748489 1.00 SLC15A2 (0.46) SLC15A2ERAP2LNPEPTERTSLC6A5
SCHEMBL31433209 0.98 SLC15A2 (0.45) SLC15A2ERAP2LNPEPTERTSLC6A5
SCHEMBL31453807 0.96 SLC15A2 (0.50) SLC15A2ERAP2LNPEPTERTSLC6A5
SCHEMBL34464922 0.93 SLC15A2 (0.42) SLC15A2ERAP2LNPEPERAP1OPRD1
SCHEMBL4958843 0.92 SLC15A2 (0.50) SLC15A2ERAP2LNPEPTERTERAP1
SCHEMBL4958851 0.92 SLC15A2 (0.50) SLC15A2ERAP2LNPEPTERTERAP1
SCHEMBL8832514 0.92 TERT (0.44) SLC15A2ERAP2LNPEPTERTMMP2
SCHEMBL2823387 0.92 TERT (0.44) SLC15A2ERAP2LNPEPTERTMMP2
SCHEMBL8832652 0.91 TERT (0.44) SLC15A2ERAP2LNPEPTERTMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120943953-B Monoclonal antibody specifically binding to EsxA and therapeutic reagent thereof 西京学院 2026-05-15 CN claimed
CN-115466308-A Anti-migration and anti-invasion 18 beta-glycyrrhetinic acid-HGK, synthesis, anti-cancer metastasis activity and application thereof 首都医科大学 2022-12-13 CN claimed
CN-111793113-B Synthesis, activity and application of dihydroxymethyl tetrahydrocarboline-3-formyl-The-HGK 首都医科大学 2022-08-05 CN claimed
CN-112898376-B Dioxane-modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, antitumor activity thereof and application thereof 首都医科大学 2022-06-24 CN claimed
CN-112094317-B His-Gly-Lys modified methotrexate, synthesis, anti-transfer activity and application thereof 首都医科大学 2022-04-22 CN claimed
CN-112979751-B Dioxane-modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, anti-inflammatory activity thereof and application thereof 首都医科大学 2022-04-22 CN claimed
CN-112010926-B KGH and hydroxymethyl modified benzimidazole quinazolines, synthesis, activity and applications thereof 首都医科大学 2022-04-22 CN claimed
CN-112898380-B Dioxohexa-ring modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, antithrombotic activity thereof and application thereof 首都医科大学 2022-04-22 CN claimed
CN-112094322-B His-Gly-Lys modified methotrexate, synthesis, antitumor activity and application thereof 首都医科大学 2022-04-22 CN claimed
CN-120943953-B Monoclonal antibody specifically binding to EsxA and therapeutic reagent thereof 西京学院 2026-05-15 CN disclosed
CN-115466308-A Anti-migration and anti-invasion 18 beta-glycyrrhetinic acid-HGK, synthesis, anti-cancer metastasis activity and application thereof 首都医科大学 2022-12-13 CN disclosed
CN-115466308-A Anti-migration and anti-invasion 18 beta-glycyrrhetinic acid-HGK, synthesis, anti-cancer metastasis activity and application thereof 首都医科大学 2022-12-13 CN disclosed
CN-115466307-A 18 beta-glycyrrhetinic acid-Glu-Asp-Gly resistant to adhesion migration and invasion and synthesis, activity and application thereof 首都医科大学 2022-12-13 CN disclosed
CN-111793113-B Synthesis, activity and application of dihydroxymethyl tetrahydrocarboline-3-formyl-The-HGK 首都医科大学 2022-08-05 CN disclosed
EP-0522004-A1 USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING PROCYTE CORPORATION (US) 1993-01-13 EP disclosed
EP-0514460-A1 ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF PROCYTE CORPORATION (US) 1992-11-25 EP disclosed
US-5164367-A Complexes with peptides PROCYTE CORPORATION (US) 1992-11-17 US disclosed
US-5118665-A Enhance or restore resistance of mammals to damage caused by release of reactive oxygen species PROCYTE CORPORATION (US) 1992-06-02 US disclosed
WO-1991014437-A2 USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING PROCYTE CORPORATION (US) 1991-10-03 WO disclosed
WO-1991012267-A1 ANTI-OXIDATIVE AND ANTI-INFLAMMATORY METAL:PEPTIDE COMPLEXES AND USES THEREOF PROCYTE CORPORATION (US) 1991-08-22 WO disclosed